- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
ASCO: A Time to Reflect and Learn
As conference season ramps up, it's a good time to reflect on the impact advances in pharma have on patients.
Mike Hennessy Jr.
President and CEO
of MJH Life Sciences
As I write this, it is three days before the ASCO Annual Meeting, the first in a series of conferences that arrive in rapid succession, such as the Consortium of Multiple Sclerosis Centers (CMSC), the American Society of Mass Spectrometry (ASMS), the American College of Rheumatology (ACR), and the many more conferences that the healthcare brands under MJH Life Sciences® cover. For the Pharmaceutical Executive® audience, we also look forward to BIO at the beginning of June and DIA at the end of the month, both in Boston this year.
However, it is ASCO that holds a special place at the heart of MJH. Our flagship oncology brands include OncLive®, Targeted Oncology™, CancerNetwork®, and CURE®. We also offer academic and community oncologists, nurses, patients, and all those involved with the cancer care journey with an unmatched selection of resources. These include our live educational events along with digital and print solutions that deliver the peer-to-peer education needed for improving patient outcomes. From video editorials to conference coverage, we independently produce content that combines objective facts and expert insights for the cancer care community.
Projects on the docket for MJH this year for ASCO are entering triple digits and include satellite symposia, panel discussions, and live workshops. We are renting studio space in Chicago, and all three of our studios will be running at full capacity as we complete close to 50 video projects across groups. Additionally, PER® will be hosting more than a dozen symposia at different hotels around the convention through the ASCO meeting.
On both sides of our business—healthcare and industry sciences—we continuously hear about those who have entered the field of oncology in a variety of roles to make an impact on those suffering from cancer. Whether it is a physician, a nurse, a pharma CEO, or clinical researcher, many are on the front lines with their stories that touch a tremendous amount of people with their compassion. We would like to thank them all for bringing us one step closer to a world without cancer.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
Solving One of the Hardest Questions in Cancer: How Do We Ensure Patient Access to Medicines?
October 16th 2024Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.
Leverage AI to Lower Cost, Barriers to Cell Therapies
October 10th 2024Off-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system's rejection and navigating the FDA's approval process are crucial challenges.
